Ah, I skipped over the part where it said "who have progressed on/after all approved drugs for CRC". Yes, BSC is usually reserved for when there are no other treatment options, which was why the inclusion criteria on clinicaltrials.gov surprised me. It makes more sense now.
So SNY/REGN don't have anything to worry about in this case, but regorafenib will compete with perifosine (if the latter manages to meet its primary endpoint).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.